Scoop: Drug safety software company RxLogix exploring a sale

RxLogix, a privately held drug safety software provider, is pursuing a sale, Axios Pro has learned from multiple sources.

Inside the room: CrossTree is running the auction that is marketing RxLogix on nearly $30 million of EBITDA.

• First-round bids were collected last week, per one source.